EMA Authorised: Zeffix (lamivudine) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

EMA authorised Zeffix (lamivudine) for chronic hepatitis B, with GlaxoSmithKline Trading Services Limited as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Zeffix (lamivudine)

Snippet

Status: Authorised. Therapeutic area: Hepatitis B, Chronic. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 26/05/2025